News

Deepak Bhatt, MD, MPH, discusses the need to improve in-hospital initiation and uptitration of guideline-directed medical therapy in heart failure.

A new study found balance and falling were linked to an increased risk of all-cause mortality, as well as cause-specific mortality from cardiovascular disease and diabetes.

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

In this interview, Palmer shares several of the key findings and their implications for the future of this patient population.

According to a new study, overall outpatient mental health care increased from 11.2% to 12.4% between 2018 and 2018. However, for individuals with serious psychological distress, the rate of care decreased from 46.5% to 40.4%.

Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

According to a new systematic review and meta-analysis, roxadustat's efficacy remains consistent across varying inflammation levels in patients with chronic kidney disease.

The FDA set its target action date for October, with this sNDA being supported by two phase 1 safety studies on AK patients.

This cohort study’s findings highlight the value of a smoking status assessment at the time of melanoma diagnoses.

Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.

SARS-CoV-2 antibody levels did not change significantly in patients receiving originator adalimumab, while patients receiving the biosimilar experienced a significant decrease.

This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

These data indicate that in the US, the outpatient management of patients with pulmonary embolism identified as lower-risk may continue to be underutilized.

A study found 27.5% of individuals who had an emergency department for cannabis use were diagnosed with a new anxiety disorder within 3 years. However, only 5.6% of the general population developed a new anxiety disorder.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

This analysis of trends in e-cigarette prevalence highlights several important trends among smokers, updating the current literature with new information about demographics and other data.

A new study found patients with schizophrenia on lurasidone had an effect size change of 0.33 on the PANSS prosocial subscale, suggesting improvements in social functioning.

Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.

Long-term anti-VEGF treatment for nAMD was linked to a reduction in mortality risk, with a slight increase in CVD risk, across 16-years of follow-up in Denmark.

In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.

A pooled analysis showed patients on cariprazine for major depressive disorder had only mild to moderate treatment-emergent adverse events.

Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.